Background: Many studies have explored the relationship between the expression level
of miRNAs and the prognosis of patients with laryngeal cancer (LC). However, the prognostic value
of miRNA in LC patients has not been comprehensively evaluated.
Methods: PubMed, Web of Science, Embase, and Cochrane Database of Systematic Reviews were
extensively searched for all studies published before the end of February 2020 that investigated the
correlation between miRNA expression level and clinical prognosis in patients with LC.
Results: Twenty-one studies involving 1784 patients were included in our meta-analysis. The survival
endpoints of OS and DFS were 1.69 (95% CI 1.45-1.98; p < 0.05) and 3.62 (95% CI 2.34–5.62;
p < 0.05), respectively. Both OS and DFS results were statistically significant. Subgroup analyses
were performed by evaluating the effects of miR-196b, miR-375, and miR-21 on OS and the effects
of miR-34c-5p on DFS. The results obtained for miR-196b and miR-34c-5p were statistically
Conclusion: The results indicate that miRNAs, as prognostic biomarkers for LC, play an important
role in clinical value. In particular, miR-196b and miR-34c-5p have the potential to be used as prognostic
biomarkers. However, further large-scale cohort studies based on these miRNAs are urgently
needed to validate their clinical value and help determine the direction of future clinical work in